Sanofi (SNYNF)
| Previous Close | 94.25 |
| Open | 95.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 94.00 - 95.00 |
| 52 Week Range | 86.12 - 111.35 |
| Volume | |
| Avg. Volume | 42,780 |
| Market Cap | 118.153B |
| Beta (5Y Monthly) | 0.45 |
| PE Ratio (TTM) | 20.52 |
| EPS (TTM) | 4.58 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 4.06 (4.32%) |
| Ex-Dividend Date | May 13, 2024 |
| 1y Target Est | N/A |
GlobeNewswirePress Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance
Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance Paris, April 25, 2024 Sales growth of 6.7% at CER and business EPS(1) of €1.78 Dupixent sales up 24.9% to €2,835 million, on target to deliver ~€13bn in 2024Pharma launches up 90.5% to €606 million, led by Nexviazyme and ALTUVIIIOVaccines sales up 5.6%, boosted by BeyfortusConsumer Healthcare (CHC) up 9.0%, benefiting from the Qunol acquisition in Physical and Mental Wellness and strong Digestive Wellness performa
ZacksWhat's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.
BloombergSanofi Asks Banks to Pitch for $20 Billion OTC Spinoff
(Bloomberg) -- French drugmaker Sanofi has asked banks to pitch for roles on the separation of its consumer-health business, according to people familiar with the matter, one of the biggest deals likely to happen in Europe this year. Most Read from BloombergTaylor Swift Is Proof That How We Critique Music Is BrokenBiden’s Gains Against Trump Vanish on Deep Economic Pessimism, Poll ShowsBiden’s New Chopper Is Demoted After Scorching White House LawnTesla Soars as Musk’s Cheaper EVs Calm Fears Ove
